Degroof Petercam initiates coverage of Oncodesign Precision Medicine

Dijon (France), April 18, 2024, at 6:00pm CEST– Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, today announced that Degroof Petercam, a brokerage firm and investment bank, has initiated coverage of its shares.

Analysts note